DavidQuinnMD

Clinical Trials

• S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Start of enrollment: 2006 Aug 01

  Completed

  Phase 3

• Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma Start of enrollment: 2004 Nov 01

  Completed

  Phase 2

• Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy. Start of enrollment: 2001 Mar 01

  Completed

  Phase 2

• Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer Start of enrollment: 2005 Apr 30

  Completed

  Phase 2

• Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) Start of enrollment: 2005 Aug 18

  Unknown status

  Phase 1, Phase 2

• Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium Start of enrollment: 2006 Jun 01

  Terminated

  Phase 2

• Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Start of enrollment: 2006 Oct 23

  Active, not recruiting

  Phase 1, Phase 2

• 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01

  Active, not recruiting

  Phase 2

• Short-Term Fasting: Impact on Toxicity Start of enrollment: 2009 Jul 09

  Active, not recruiting

  Not Applicable

• A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11

  Completed

  Phase 1

• Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2009 Oct 29

  Active, not recruiting

  Phase 1, Phase 2

• Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder Start of enrollment: 2011 Jun 13

  Terminated

  Phase 2

• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08

  Active, not recruiting

  Phase 3

• Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30

  Completed

  Phase 2

• Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2012 Aug 01

  Completed

  Phase 2

• Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01

  Completed

  Phase 2

• Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer Start of enrollment: 2013 Jan 29

  Active, not recruiting

  Not Applicable

• S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08

  Active, not recruiting

  Phase 3

• A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13

  Completed

  Phase 3

• Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer Start of enrollment: 2015 Nov 11

  Completed

  Phase 2

• Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Start of enrollment: 2015 Dec 01

  Completed

  Phase 1, Phase 2

• Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma Start of enrollment: 2016 Feb 23

  Completed

  Phase 1

• Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Start of enrollment: 2016 Mar 09

  Terminated

  Phase 2

• A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Start of enrollment: 2016 Jun 01

  Terminated

  Phase 1

• Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Start of enrollment: 2018 Jul 20

  Active, not recruiting

  Phase 2

• Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer Start of enrollment: 2018 Nov 21

  Active, not recruiting

  Phase 2

• sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2019 Sep 20

  Active, not recruiting

  Phase 2

• Join now to see all